Jeff Eiseman
Long only, deep value, special situations

Why PharmAthene Will Win Its Suit With SIGA And How Much It Will Collect

G. Hudson, a SIGA (NASDAQ:SIGA) investor wrote "SIGA or PharmAthene: Who Really Won?" I responded with "SIGA Technologies Vs. PharmAthene: A Comprehensive Analysis of the Legal Issues." As a result of the exchanges following both articles and re-examining key documents, my thinking about the issues has both expanded and become more sharply focused. This article discusses the legal, economic and ethical issues involved, and calculates how much revenue PharmAthene will receive from SIGA under various scenarios. Below, I provide essential background information, pose six key questions and for each question, (1) explain why its answers matter, and (2) provide answers that have been expressed by both SIGA and PharmAthene (NYSEMKT:PIP) investors. The article closes with two

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details